.avif)
The compounded GLP-1 landscape shifted decisively in 2026, and the clinics that did not see it coming are now the ones scrambling.
In February 2026, the FDA publicly stated its intent to take action against non-FDA-approved GLP-1 drugs. On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the regulatory mechanism that governs what large-scale compounding operations may produce. If finalized, that proposal closes the large-scale compounding pathway for the three most widely prescribed GLP-1 medications.
The enforcement posture is not new. As of early 2025, the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials.
For GLP-1 clinic operators, the message is straightforward: the programs that survive this environment are the ones with compliant Medical Directorships, documented Good Faith Exam (GFE) protocols, and physician oversight that holds up to scrutiny — not just to onboarding.
Running a GLP-1 weight loss program is not the same as adding a treatment to your menu. It is a medical prescribing program that requires a physician governance structure, not just a physician signature on an intake form.
The minimum requirements for a compliant GLP-1 program in 2026:
1. A Medical Director with prescribing oversight A Medical Director for a GLP-1 program is responsible for more than clinical protocols. They are the physician of record for the prescribing program. That means their oversight extends to:
2. Good Faith Exam (GFE) protocols built for audit conditions The Good Faith Exam is the foundation of every GLP-1 prescription. State boards that investigate GLP-1 programs look at GFE documentation first. The two failure patterns that appear in most enforcement actions are:
A GFE protocol that was adequate in 2023 may not meet the current standard. Boards are flagging rubber-stamping patterns — high prescription volume with uniform or minimal documentation — as a primary enforcement trigger.
3. Compounding pharmacy oversight The FDA's enforcement priorities are explicit: compounding without documented medical necessity, unlicensed manufacturing, misleading marketing, improper storage and shipping, poor API sourcing, and the use of research-grade ingredients not intended for human use.
Your Medical Director must have documented oversight of your compounding pharmacy relationship. This means a direct, documented QA relationship — not a statement that "we use a licensed pharmacy." The physician must be the one verifying sourcing compliance, reviewing Certificates of Analysis, and confirming that the pharmacy holds the correct license type for your program model.
4. Semaglutide base form verification One of the most commonly cited sourcing violations in FDA enforcement actions is the use of semaglutide sodium or acetate (salt forms) rather than the base form. A compounded drug product that combines semaglutide API with another API, such as vitamin B12, will be considered essentially a copy of a commercially available drug product under certain conditions. Your Medical Director must confirm the base form explicitly in writing with your compounding pharmacy — not assume it.
Most GLP-1 clinics operated under one of two compounding pathways. Understanding which one applies to your program determines your current legal exposure:
503B outsourcing facilities produce medications in bulk for office use without a patient-specific prescription. The April 30, 2026 FDA proposal targets this pathway specifically — proposing to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list because there is no longer a clinical need for outsourcing facilities to compound these drugs now that drug shortages have been resolved.
503A state-licensed pharmacies compound patient-specific prescriptions based on documented individual medical necessity. This pathway remains narrower but is not yet closed. The period of enforcement discretion for 503A compounding of semaglutide ended in April 2025. Compounding under 503A now requires genuine, documented medical necessity for each individual patient — not a protocol-level prescription.
If semaglutide and tirzepatide are removed from the 503B bulks list, most current compounded supply would be affected significantly. Most current compounded supply is produced through 503B outsourcing facilities, which would no longer be able to compound them in bulk.
The operational implication: programs that have not already shifted toward documented individual medical necessity documentation for each patient are the most exposed.
The FDA is accepting public comments through June 29, 2026, before making a final determination. If finalized:
Programs that are already operating with individualized medical necessity documentation, physician-reviewed GFE protocols, and a compliant 503A pharmacy relationship are best positioned to continue operating. Programs that relied on bulk compounded supply without that infrastructure are facing a genuine compliance cliff.
The GFE standard for GLP-1 prescribing has tightened significantly since the program launched. What boards currently look for:
Synchronous encounter Most boards require a real-time video or in-person evaluation for first-time GLP-1 prescriptions. Asynchronous text-only intake forms are no longer accepted as adequate GFE documentation in most jurisdictions. Platforms that entered states requiring synchronous encounters with async-first models have faced prescription voiding and forced platform re-architecture.
BMI verification Photo verification or in-clinic measurement is required — patient self-report alone does not satisfy the documentation standard in most states.
Baseline labs — CMP, TSH, HbA1c, and Lipid Panel — completed before the first dose is the current clinical standard for GLP-1 prescribing. Most 2026 board guidelines, including those in Georgia, now list the Lipid Panel as recommended pre-treatment given the cardiometabolic profile of GLP-1 patients. All four must be documented in the chart, not assumed.
Contraindication screening MTC/MEN 2 history, pancreatitis, and severe GI conditions must be screened and documented at every visit — not just the initial one.
Titration and follow-up schedule A documented follow-up schedule with side-effect monitoring at each encounter is the current board standard. Volume without follow-up documentation is one of the rubber-stamping patterns boards flag in investigations.
The phrase "physician oversight" is used loosely in the GLP-1 market. What it actually means in the context of a compliant Medical Directorship:
Your license took years to build. The physician oversight structure protecting your prescribing program should match that standard.
Access Plus Health provides dedicated Medical Directorships for GLP-1 programs — structured for audit conditions, not just for onboarding.
Every GLP-1 Medical Directorship includes:
The enforcement environment is tightening. The programs that continue operating compliantly through 2026 and beyond are the ones that built physician governance infrastructure before they needed it.
To discuss your program's current compliance structure, visit accessplushealth.com or call (213) 205-0946.
This article is for informational purposes only and does not constitute legal or medical advice. FDA regulations and state requirements are subject to change — consult qualified legal and medical counsel before making prescribing decisions.
.avif)
.svg)
.png)
